Treatment Strategies With Integrative Chiropractic for Migraines

Find solutions for your migraines with integrative chiropractic treatment and reclaim your comfort and well-being.

An Introduction to Modern Migraine Management: From Pathophysiology to Precision Treatment

Welcome to Health Voice 360. I am Dr. Alexander Jimenez, and as both a Doctor of Chiropractic and a Family Nurse Practitioner, I have always focused on integrating diverse, evidence-based approaches to manage complex health conditions. Migraine is one such condition that profoundly impacts my patients’ lives, and it demands a nuanced, comprehensive understanding from us as clinicians. In this educational post, I aim to unravel the intricate mechanisms of migraine and explore revolutionary advances in its diagnosis and pharmacological management. We will embark on a detailed journey, starting with the critical importance of accurate diagnosis, moving through an in-depth exploration of the underlying pathophysiology that drives migraine attacks, and culminating in a review of the modern therapeutic landscape. Understanding why a migraine happens is the first step to treating it effectively.

Our exploration begins by establishing a foundational understanding of what migraine truly is, differentiating it from other common headache disorders. Too often, in my clinical practice, I see patients who have been misdiagnosed for years with “sinus headaches” or “tension headaches,” when in fact they are suffering from migraine. We will dissect the precise diagnostic criteria set forth by the International Classification of Headache Disorders (ICHD-3) and explore practical, high-yield screening tools like the ID Migraine™ screener. Before diagnosis, however, we will emphasize clinical vigilance, systematically reviewing the SNOOP mnemonic to identify “red flags” for potentially dangerous secondary headaches.

Next, we will explore the contemporary neurobiological model of migraine pathophysiology. This includes examining the central role of the trigeminovascular system, dysregulation in key brain areas such as the hypothalamus and brainstem, and the pivotal role of neuropeptides. Specifically, we will illuminate the function of Calcitonin Gene-Related Peptide (CGRP), a key player in initiating and sustaining the pain and inflammation of a migraine attack. We will explore its widespread expression in the trigeminal system, its release during a migraine attack, and its multifaceted role in vasodilation, neurogenic inflammation, and pain propagation. In parallel, we will discuss the role of serotonin and its inverse relationship with CGRP, explaining the long-standing efficacy of serotonin agonists, like the triptans, in acute migraine management.

With this pathophysiological foundation, we will then transition to a comprehensive review of established and emerging therapeutic strategies. We will categorize treatments as acute (abortive) and preventive (prophylactic). For chronic migraine, we will move beyond a superficial understanding to detail the presynaptic action of OnabotulinumtoxinA (Botox), specifically how it cleaves the SNAP-25 protein within the SNARE complex. We will also cover the standardized PREEMPT protocol, outlining the 31 injection sites across seven specific muscle groups. Next, the post shifts to the groundbreaking class of CGRP antagonists, comparing monoclonal antibodies (mAbs) with the small-molecule gepants. This dual-pronged attack on the CGRP pathway represents one of the most significant breakthroughs in migraine medicine in decades. Our review of acute therapies will cover standard-of-care medications, including the triptans (5-HT1B/1D agonists), and introduce newer classes, such as the ditans (lasmiditan, a 5-HT1F agonist) and the gepants (ubrogepant and rimegepant), highlighting how these novel agents offer targeted solutions, particularly for patients with contraindications to traditional treatments. Throughout this post, I will integrate clinical observations from my own practice at HealthVoice360.com, providing real-world context to the cutting-edge research presented by leaders in the headache field. This is not a lecture, but a shared exploration of a disorder that affects millions, aimed at strengthening our collective ability to provide compassionate, effective care.

Differentiating Migraine: Beyond the “Bad Headache”

In my clinical practice, one of the first and most critical steps in helping a patient is achieving an accurate diagnosis. The term “headache” is often used as a catch-all, but the underlying cause can vary dramatically. Migraine is a specific, debilitating neurological disorder, not just a severe headache. Distinguishing it from other headache types, particularly secondary headaches that may signal a more sinister underlying condition, is paramount.

The SNOOP Mnemonic: Red Flags for Secondary Headaches

Before we can confidently diagnose a primary headache disorder like migraine, we must first be vigilant for “red flags” that suggest a secondary cause—meaning the headache is a symptom of another condition. The SNOOP mnemonic is an indispensable tool I use daily to screen for these warning signs. It helps us organize our thinking and ensure we don’t miss something critical.

• S – Systemic Symptoms: The first ‘S’ prompts us to ask about systemic or constitutional symptoms accompanying the headache. Does the patient report fever, unexplained weight loss, or generalized muscle aches (myalgias)? The presence of these symptoms alongside head pain should raise immediate concern for an underlying systemic process. In my clinical experience, this could point towards an infectious etiology like meningitis or another inflammatory condition affecting the meninges (the protective membranes surrounding the brain and spinal cord). A patient presenting with a severe headache, stiff neck, and fever requires urgent evaluation, not a migraine prescription.
• S – Secondary Risk Factors: The second ‘S’ stands for secondary risk factors. We must consider the patient’s overall health profile. Is this an individual living with HIV, undergoing cancer treatment, or who is currently pregnant? These conditions can predispose individuals to specific secondary headache types. For instance, a patient with a history of cancer presenting with a new headache pattern could have metastatic disease. In pregnancy, conditions like pre-eclampsia or cerebral venous thrombosis can manifest as headaches. A new-onset headache in these populations warrants a much lower threshold for investigation.
• N – Neurologic Exam Findings: This is a crucial, non-negotiable part of any headache evaluation. A thorough neurologic exam is essential. Any focal neurologic deficits, such as weakness in one limb, facial droop, or sensory loss, are major red flags. Other concerning findings include new-onset confusion, a first-time seizure accompanying the headache, or papilledema (swelling of the optic disc) on fundoscopic exam. Papilledema indicates increased intracranial pressure and is a medical emergency. Any of these findings necessitates immediate, advanced imaging and referral to a higher level of care, such as an emergency department.
• O – Onset: The character of the headache’s onset is incredibly revealing. A sudden or “thunderclap” onset, where the pain reaches its maximum intensity within a minute or less, is the classic presentation of a subarachnoid hemorrhage. Patients often describe this as “the worst headache of my life.” This is starkly different from a typical migraine attack. While migraine can be severe, its onset is usually more gradual. As you talk with patients, you’ll find that migraine pain tends to build, waxing and waning over minutes to hours. A thunderclap headache that goes from zero to a ten-out-of-ten intensity almost instantaneously demands immediate investigation to rule out a bleed.
• O – Older Age of Onset: Most individuals with migraine begin experiencing attacks in adolescence or early adulthood. Therefore, a new type of headache after age 50 is another significant red flag. While it’s possible for migraine to begin later in life, we must consider other age-related pathologies. A prime example is giant cell arteritis (GCA), also known as temporal arteritis. This vasculitis (inflammation of blood vessels) primarily affects older adults. While the head pain can mimic migraine, key distinguishing features often include jaw claudication (pain with chewing), scalp tenderness (pain when touching the head or brushing hair), and associated systemic symptoms like weight loss and fatigue. GCA is a self-limiting condition but requires prompt treatment with corticosteroids to prevent irreversible vision loss.
• P – Pattern Change, Precipitants, Positional Changes, Papilledema: This final letter encompasses several important considerations.

• • Pattern Change: For a patient with a long-established history of migraine, any significant change in headache frequency, severity, or character warrants concern. For example, a patient I’ve been seeing for years with classic menstrual migraine who suddenly develops a persistent, daily, low-grade headache requires re-evaluation and, most likely, neuroimaging to rule out new intracranial pathology.
  • Precipitants: Ask whether specific actions trigger the headache. If a patient reports that their head pain occurs only with coughing, sneezing, or bearing down (a Valsalva maneuver), this raises suspicion for a structural issue, such as a space-occupying lesion (like a tumor or cyst) or a Chiari malformation, which can increase intracranial pressure with these activities.
  • Positional Changes: The relationship between head pain and body position is highly diagnostic. A classic example is a low-pressure headache (spontaneous intracranial hypotension), where the patient feels fine lying flat but develops a severe headache when sitting or standing. The pain resolves completely when the patient lies down again. Conversely, headaches that are worse when lying down can suggest increased intracranial pressure.
  • Pain with Sexual Activity: Headaches associated with sexual activity, particularly orgasmic or pre-orgasmic headaches, can be benign. However, because they often involve a Valsalva-like effect, they can also signal an underlying vascular issue or a space-occupying lesion and warrant careful evaluation, especially on first occurrence.

By systematically working through the SNOOP mnemonic with every patient presenting with headache, we build a crucial safety net, ensuring we identify and appropriately manage potentially life-threatening conditions before labeling the pain as a primary headache disorder.

The Epidemiology of Migraine: A Hidden Epidemic

Once we have ruled out secondary causes, we can focus on primary headache disorders. Among these, migraine is not only one of the most common but also one of the most misunderstood and underdiagnosed. It is far more than “just a headache.” Migraine is a complex neurological disease that affects an estimated 10-12% of the global population, making it one of the most common and burdensome health conditions worldwide. The World Health Organization classifies severe migraine attacks as among the most disabling conditions, comparable to quadriplegia, dementia, and active psychosis. The ripple effects extend beyond the individual, impacting families, workplaces, and economies through lost productivity and significant healthcare costs.

The statistics are staggering and paint a picture of a widespread public health issue.

• Globally, more than a billion people suffer from migraine, making it one of the most prevalent neurological disorders.
• There is a significant gender disparity: migraine affects approximately one in five women and one in sixteen men. This hormonal link is a key area of research, with many women experiencing fluctuations in their migraine patterns related to their menstrual cycle, pregnancy, and menopause.
• It’s not just an adult disorder. Among children, about one in eleven experience migraine. Interestingly, before the onset of puberty and its associated hormonal shifts (menarche), the prevalence is roughly equal between boys and girls, highlighting that while hormones are a major modulator, they are not the sole factor.
• The impact is felt at the household level, with surveys indicating that one in four households in the United States includes at least one person with migraine.

Given these numbers, who is managing this vast population of patients? It’s not primarily headache specialists or even neurologists. Primary care is the front line of migraine care. Research indicates that approximately 70% of individuals with migraine are managed by primary care clinicians. This reality places an immense responsibility on us—nurse practitioners, physician assistants, and primary care physicians—to be experts in this field. We must be proficient in diagnosis, knowledgeable about the underlying pathophysiology, and up to date on the full spectrum of available treatments, from long-standing therapies to the latest innovations. Millions of our patients’ well-being depends on it.

The Diagnostic Blueprint: Unpacking the ICHD-3 Criteria for Migraine

Accurately diagnosing migraine requires a structured approach. While patient stories are diverse, the International Classification of Headache Disorders, 3rd edition (ICHD-3), provides the standardized criteria we use to make a definitive diagnosis. It helps us move from subjective complaints to an objective classification. Let’s break down the criteria for the most common form: migraine without aura.

A patient must have had at least five attacks that meet the following criteria. The headache attacks themselves must last 4 to 72 hours if left untreated or unsuccessfully treated. Within that timeframe, the headache must have specific characteristics.

The ICHD-3 criteria are organized into two groups. The patient must have at least TWO of the following four pain characteristics:

1. Unilateral Location: The pain is located on one side of the head. This is a classic feature, but it’s important to counsel patients that the side can shift between attacks or even during a single attack. I also stress that about 40% of migraine attacks are bilateral, so the absence of one-sided pain does not rule out migraine.
2. Pulsating Quality: The pain is described as throbbing, pounding, or pulsating. This sensation is thought to relate to dilation of cranial blood vessels and sensitization of the surrounding nerves.
3. Moderate to Severe Intensity: The pain is not a minor annoyance. It is significant enough to interfere with or even prohibit daily activities. On a 10-point scale, patients often rate their migraine pain between a 5 and a 10.
4. Aggravation by Routine Physical Activity: This is a highly specific and differentiating feature. The pain worsens with simple movements like walking, climbing stairs, or even just moving from sitting to standing. This contrasts with a tension-type headache, which often feels better with gentle movement or activity.

In addition to the pain characteristics, the patient must also have at least ONE of the following associated symptoms during the headache:

1. Nausea and/or Vomiting: The gastrointestinal distress associated with migraine can be as debilitating as the pain itself. The link between the brain and the gut is very strong in migraine, and these symptoms are a key part of the attack for many.
2. Photophobia and Phonophobia: This is a heightened sensitivity to light (photophobia) and sound (phonophobia). During an attack, a normally lit room can feel blindingly bright, and normal conversation can sound painfully loud. This is why many people with migraine seek refuge in a dark, quiet room.

It’s crucial to understand the flexibility within these criteria. A patient could have a bilateral, non-throbbing pressure headache that is severe, worsened by movement, and accompanied by nausea. Under ICHD-3 criteria, this is unequivocally migraine. This variability is why so many migraines are misdiagnosed as tension-type or sinus headaches. We must listen carefully and apply the criteria systematically, recognizing that migraine presents on a spectrum.

The ID Migraine™ Screener: A Rapid and Reliable Tool

In a busy primary care clinic, time is of the essence. While a full history guided by ICHD-3 is the gold standard, a quick, validated screening tool can be incredibly effective. The ID Migraine™ screener, developed by Dr. Richard Lipton and his team, is an excellent example. It includes just three simple yes-or-no questions based on the most debilitating migraine symptoms. The acronym PIN helps us remember them:

• P – Photophobia: “In the last three months, has a headache limited your activities for a day or more?”
• I – Impairment: “Are you nauseated or sick to your stomach when you have a headache?”
• N – Nausea: “Does light bother you when you have a headache?”

If a patient answers yes to two out of these three questions, the probability that they have migraine is 93%. This simple tool can be integrated into a routine intake questionnaire or used by a medical assistant during vital signs, flagging patients who need a more in-depth headache evaluation. It is a powerful way to quickly and accurately identify the vast number of undiagnosed migraine sufferers in our practices, provided we have already ruled out the “SNOOP” red flags.

Migraine vs. Tension-Type Headache: A Clinical Comparison

One of the most frequent diagnostic challenges is distinguishing migraine from tension-type headache (TTH). Many patients, and even some clinicians, incorrectly believe that any bilateral, non-throbbing headache is automatically a tension headache. Let’s compare these two disorders side by side to highlight the key differences.

The most powerful question to differentiate the two is: “Does routine physical activity, like walking up a flight of stairs, make your headache worse?” If the answer is yes, you should be thinking migraine. If the answer is no, and they may even report feeling a bit better after getting up, moving around, or stretching their neck, it’s much more likely to be a tension-type headache. In my clinical experience, patients with TTH can usually function through their day. Patients with migraine often cannot. When a patient comes into the office seeking care for a headache, my default assumption is migraine first, as TTH is often manageable at home.

The Full Picture of a Migraine Attack: Beyond the Headache Phase

The headache itself, though the most recognized symptom, is only one part of a multi-phase neurological event. Understanding the full continuum of a migraine attack helps us better educate patients and identify opportunities for early intervention. A complete attack can span several days.

Image Caption: The four phases of a migraine attack: Prodrome, Aura, Headache, and Postdrome, occurring around the pain-free Interictal phase.

1. The Interictal Phase: This is the period between migraine attacks. For people with episodic migraine, this is their baseline, pain-free state. A key goal of preventive therapy is to lengthen this phase as much as possible.
2. The Prodrome Phase: Occurring hours to a day or two before the headache pain begins, the prodrome includes premonitory symptoms that signal an impending attack. About 70% of people with migraine experience a prodrome. The hypothalamus generates these symptoms and can include:

• • Yawning
  • Food cravings
  • Mood changes (irritability, depression, or euphoria)
  • Fatigue
  • Neck stiffness (often misattributed as the cause of the headache, when it is actually an early symptom)
  • Increased urination
  • Cognitive difficulties, like trouble finding words or concentrating.

Recognizing these personal prodromal cues can empower patients to take acute medication early, often before the pain even starts, which can dramatically improve its effectiveness.

• The Aura Phase: Experienced by about 30% of people with migraine, the aura consists of a set of transient, fully reversible neurological symptoms that typically precede or sometimes accompany the headache. Auras usually develop over 5-20 minutes and last for less than 60 minutes.

• • Visual Aura: This is the most common type. Importantly, migraine auras are typically positive phenomena, meaning something is added to the visual field. Patients describe seeing bright, shimmering, zigzag lines (fortification spectra), flashing lights, or spots. This visual disturbance often starts centrally and expands outward toward the periphery. This is different from the symptoms of a transient ischemic attack (TIA), which typically involve negative phenomena like a loss of vision (a curtain coming down over the visual field) or a distinct visual field cut.
  • Sensory Aura: This can involve tingling or numbness that often starts in the fingers of one hand and slowly migrates up the arm and sometimes to the face and tongue.
  • Language Aura: This may involve difficulty speaking or understanding language (aphasia).

• The Headache Phase: This is the pain phase we’ve discussed in detail, lasting 4-72 hours and accompanied by nausea, vomiting, photophobia, and phonophobia.
• The Postdrome Phase: After the headache pain subsides, the attack is often not over. The postdrome, sometimes called the “migraine hangover,” can last for another 24-48 hours. During this phase, patients often feel completely drained, fatigued, and foggy. They may have difficulty concentrating and experience lingering muscle aches, particularly in the neck and shoulders. The scalp can also be tender to the touch (cutaneous allodynia). Acknowledging the postdrome is important for validating the patient’s experience; the disability from migraine does not necessarily end when the pain stops.

Recognizing this entire timeline helps frame migraine not as an isolated pain event, but as a complex, multi-day neurological process that affects the entire body.

The Modern Understanding of Migraine Pathophysiology

For many years, migraine was thought to be a purely vascular problem—blood vessels in the brain constricted (causing aura) and then dilated (causing pain). This “vascular theory” has been largely replaced by a much more sophisticated neurobiological model. We now understand migraine as a disorder of brain hyperexcitability and sensory dysregulation, with the trigeminovascular system playing a central role. The prevailing theory, supported by decades of research, centers on the activation and sensitization of the trigeminovascular system. This system comprises the trigeminal nerve (the fifth cranial nerve), its extensive network of nerve fibers that innervate the cranial blood vessels and meninges (the protective layers covering the brain), and its connections within the brainstem and higher cortical centers.

Let’s break down the key components: central and peripheral.

A New Paradigm: Understanding the Central Mechanisms of Migraine

Hello, I’m Dr. Alexander Jimenez. Throughout my years in clinical practice, combining the perspectives of a Doctor of Chiropractic and a Family Nurse Practitioner, I have had the privilege of guiding countless patients through the complexities of chronic conditions. Among the most challenging and misunderstood of these is migraine. My clinical observations at HealthVoice360.com consistently reveal that patients are often frustrated by simplistic explanations that fail to capture the true, multi-system nature of their experience. We now understand that migraine is not simply a blood vessel problem; it’s a disorder of the brain itself.

The current scientific consensus points to a central dysregulation, a kind of “wonkiness,” within specific brain regions that predisposes an individual to migraine attacks. We believe there is a strong genetic predisposition, as approximately 70% of individuals with migraine have at least one close relative with the disorder. This genetic loading creates a brain that is inherently more sensitive to changes in the internal and external environment.

• The Hypothalamus: The Migraine Generator? Increasing evidence points to the hypothalamus as a key initiator of migraine attacks. This crucial structure lies at the epicenter of this phenomenon, deep within the brain. The hypothalamus is a small but mighty region that acts as the body’s master regulator. It’s the command center for homeostasis, meticulously controlling fundamental functions like body temperature, hunger, thirst, fatigue, and our circadian rhythms—the sleep-wake cycle. Its role in the prodromal phase—causing symptoms like yawning, fatigue, and food cravings—suggests it is one of the first areas to become activated. When I see patients in my clinic, they often report a constellation of symptoms that begin hours, or even days, before the headache phase of their migraine. These premonitory symptoms include unexplained fatigue, food cravings (often for sweets or salty foods), mood swings, irritability, and difficulty concentrating. These are not random occurrences; they directly reflect hypothalamic dysregulation.

Leading research, utilizing advanced imaging techniques like functional MRI (fMRI), has shown that the hypothalamus becomes hyperactive in the period leading up to a migraine attack. This state of hyperexcitability, or over-stimulation, is what we believe constitutes the “migraine generator.” It’s as if the control panel for the body’s essential functions is temporarily malfunctioning, sending out erratic signals. This explains why emotions are so intricately wrapped up in the migraine experience and why an individual’s appetite and sleep-wake cycles can be so profoundly disrupted. This central piece of the puzzle is critical: a person with migraine has a baseline physiological difference in the brain, specifically within this vital regulatory region. The hypothalamus has extensive connections to other brain regions, including the limbic system (involved in emotion and memory) and the brainstem, allowing it to trigger the cascade of events that follows.

• Cortical Spreading Depression (CSD): The Basis of Aura: The neurological symptoms of aura are now believed to be caused by a phenomenon called cortical spreading depression (CSD). The migraine cascade is initiated by a trigger—which can be anything from hormonal fluctuations, stress, certain foods, or weather changes—that leads to a state of cortical hyperexcitability. This hyperexcitability can manifest as CSD, a slow-moving wave of intense neuronal and glial depolarization that spreads across the cerebral cortex at 2- 5 mm/minute. This wave of hyperactivation is followed by a longer-lasting period of neuronal suppression or silence. When CSD occurs in the visual cortex, it produces visual aura symptoms. When it moves across the somatosensory cortex, it produces sensory symptoms. CSD is a key event that links the central nervous system to the activation of the peripheral pain pathways. Whether or not an aura precedes it, this initial neuronal event triggers activation of trigeminal nerve endings wrapped around the dural and pial blood vessels. This activation is the critical step that bridges the central nervous system event (CSD) with the peripheral pain-generating mechanism.

The Peripheral Trigger: The Critical Role of the Trigeminal Nerve

This central dysregulation in the hypothalamus doesn’t exist in a vacuum. For a migraine attack to be initiated, this “primed” central system requires input, a trigger from the periphery. This is where the trigeminal nerve enters the picture, playing an essential role in the migraine cascade. The CSD wave is thought to activate the trigeminovascular system (TVS), the primary pain-signaling pathway for the head.

1. Trigeminal Nerve Activation: The trigeminal nerve (cranial nerve V), also known as the fifth cranial nerve (CN V), is the largest of the cranial nerves and is the primary sensory nerve for the head and face. Its nerve endings densely innervate the pain-sensitive structures inside the cranium, particularly the meninges and the large blood vessels (dura mater) that surround the brain. While the brain tissue itself does not feel pain, the surrounding tissues are rich with nociceptors (pain receptors). These include the meninges, which are the protective membranes covering the brain and spinal cord, particularly the outermost layer known as the dura mater, and the cerebral blood vessels, including arteries and veins that supply the brain. As you can see in the anatomical diagrams we use to educate patients, the first and most extensive branch of the trigeminal nerve, the ophthalmic division (V1), provides significant sensory input to this system. This division covers the forehead, scalp, upper eyelids, and the front of the head—areas where many of my patients describe the onset of their migraine pain. When these pain-sensitive structures are irritated or stimulated, whether by chemical, mechanical, or inflammatory triggers, they send distress signals back to the brain via the trigeminal nerve.

This organization of the nervous system is incredibly efficient. Impulses from many disparate peripheral areas—the sinuses, the teeth, the scalp, and the intracranial structures I just mentioned—are all bundled together and channeled towards a key processing center. This hub is the trigeminal nucleus caudalis (TNC), a column of gray matter located at the junction of the brainstem and the top of the spinal cord. Think of it as a central relay station where sensory information from the head and face converges before being sent to higher brain centers.

1. Release of Vasoactive Neuropeptides: When the trigeminal nerve endings are activated (by signals from CSD or other brainstem triggers), they release a cocktail of inflammatory neuropeptides. This process is known as neurogenic inflammation. Two of the most crucial neuropeptides in this inflammatory soup are Substance P and, most importantly, Calcitonin Gene-Related Peptide (CGRP). Substance P increases blood vessel permeability, allowing plasma proteins to leak onto surrounding tissue (a process called plasma protein extravasation). This leakage contributes to the inflammatory environment and further sensitizes the nerve endings.
2. Neurogenic Inflammation and the Role of CGRP: CGRP has emerged as the master molecule in migraine pathophysiology. It is a potent vasodilator, causing meningeal blood vessels to swell and become leaky. This process of neurogenic inflammation is a cornerstone of the attack. CGRP also makes the nerve fibers themselves more sensitive.
3. Pain Signal Transmission: Pain signals generated by this inflammatory soup travel from peripheral trigeminal nerve endings back to the central processing hub in the brainstem, the trigeminal nucleus caudalis (TNC). In our simplified model, you can see the trigeminal ganglion bundles and the nerve fibers ascending from the spinal cord. From the TNC, second-order neurons take over. Their job is to carry this consolidated sensory information and transmit it upwards, directly into the thalamic and hypothalamic regions of the brain. This is the critical link:

1. 1. A peripheral trigger stimulates the trigeminal nerve endings.
   2. These signals travel to the trigeminal nucleus caudalis for processing.
   3. Second-order neurons then send these impulses right up into the already hyperexcitable hypothalamus.

1. Central Sensitization: When the hypothalamus receives this barrage of signals from the trigeminal system, its pre-existing state of dysmodulation causes it to overreact. It amplifies these signals and sends too many impulses to the thalamus. The thalamus is often called the brain’s “sensory switchboard,” as it directs sensory information to the appropriate areas of the cerebral cortex for interpretation. Overloaded with signals, the thalamus forwards them to the somatosensory cortex, the part of the brain responsible for processing bodily sensations. Only at this final stage, when the cortex interprets these intense signals, does the individual perceive pain. With repeated or prolonged attacks, the neurons in the TNC and thalamus become hyperexcitable. This state, known as central sensitization, is why many people with chronic migraine develop cutaneous allodynia. In this condition, normally non-painful stimuli, like brushing their hair, touching their face, or wearing glasses, become painful. It is the brain’s pain system essentially turning its own volume up too high.

This is a gross but accurate overview of how pain is transmitted and perceived in migraine. It’s a beautiful, albeit painful, example of a cascade: a peripheral input activating a centrally dysregulated system, leading to the subjective experience of debilitating pain. In my practice, explaining this process helps patients understand that their pain is not “all in their head” in a psychological sense, but a real physiological event arising from a complex interplay between their peripheral and central nervous systems.

The Molecular Messengers: CGRP and Serotonin in Migraine Pathophysiology

Now that we have established the broad physiological framework—peripheral input into a centrally dysregulated system—let’s zoom in to the molecular level. To truly understand migraine and, more importantly, how our treatments work, we must discuss the specific neurotransmitters involved in this intricate dance.

In recent years, you have likely heard a great deal about Calcitonin Gene-Related Peptide, or CGRP. This molecule has become the superstar of migraine research, and for good reason. CGRP is a neuropeptide—a small, protein-like molecule neurons use to communicate with each other—and it is found throughout the body. Physiologically, it is one of the most powerful vasodilators known in the human system, meaning it causes blood vessels to widen or relax.

However, its role in migraine extends far beyond vasodilation. Within the trigeminal system, CGRP is a key player in pain transmission. We now have overwhelming evidence demonstrating its huge role in the migraine process. When the trigeminal nerve is activated during a migraine, it releases CGRP at nerve endings around cranial blood vessels and within the trigeminal ganglion. This release sets off a chain reaction.

To appreciate how our treatments intervene, we need to think about the structure of a synapse—the junction between two nerve cells. There is a presynaptic terminal (which releases neurotransmitters) and a postsynaptic terminal (which receives them). For many years, our primary tool for treating acute migraine attacks has been a class of drugs that target another famous neurotransmitter: serotonin.

Serotonin (5-HT) is a neurotransmitter released from the presynaptic terminal in the trigeminal system. Its role in migraine is fascinating due to its relationship with CGRP. Modern research has revealed a crucial inverse relationship between serotonin and CGRP at these neural junctions. Simply put:

• When serotonin levels are higher, CGRP release is suppressed.
• When serotonin levels are lower, CGRP release increases.

This inverse relationship is the key to understanding the mechanism of action for the triptans (e.g., sumatriptan, rizatriptan), which have been the gold standard for acute migraine treatment for decades. These medications are serotonin agonists; they mimic the action of serotonin by binding to and activating specific serotonin receptors (primarily the 5-HT1B and 5-HT1D receptors) on the presynaptic nerve terminals.

By increasing serotonergic activity at these sites, triptans effectively brake the trigeminal nerve, which in turn decreases CGRP release and its downstream effects. This reduction in CGRP leads to a cascade of beneficial effects: it constricts the painfully dilated cranial blood vessels, reduces neurogenic inflammation, and blocks the transmission of pain signals to the brainstem. This elegant mechanism, leveraging the natural balance between two powerful neurotransmitters, is how we can often stop a migraine attack in its tracks. In my clinic, helping a patient visualize this seesaw-like balance between serotonin and CGRP often brings a moment of clarity, transforming their understanding of how their medication actually works within their body.

Deep Dive into CGRP: The Master Molecule of Migraine Pain

Let’s delve deeper into Calcitonin Gene-Related Peptide (CGRP) because understanding its multifaceted role is fundamental to grasping modern migraine care. CGRP is not just a minor player; it is expressed widely and profoundly throughout the trigeminal nervous system, both centrally (within the brainstem) and peripherally (in the trigeminal ganglion and its nerve fibers).

The prevalence of CGRP is truly remarkable. Research shows it is expressed in 35 to 50 percent of neurons in the trigeminal ganglion. This isn’t a niche neurotransmitter; it is a primary language of communication for a huge portion of the sensory nerves in the head.

Interestingly, CGRP is found in specific types of nerve fibers that align perfectly with the clinical picture of migraine pain. It is predominantly located in C fibers. These are unmyelinated, small-diameter neurons that transmit sensory information relatively slowly. The type of pain they signal is often described as dull, throbbing, aching, and poorly localized—a description that resonates deeply with what my patients report during a migraine attack. This explains the persistent, grinding nature of migraine pain.

However, CGRP’s influence doesn’t stop there. While the peptide itself is in the C fibers, its receptors are found on other structures, including A-delta (A?) fibers and supportive glial cells. A-delta fibers are thinly myelinated and conduct nerve impulses much more rapidly than C fibers. They transmit sharp, well-localized initial pain. The presence of CGRP receptors on these fibers suggests that CGRP, once released, can also sensitize these faster pain pathways, contributing to the overall intensity and complexity of the pain experience. Its receptors on glial cells also implicate it in modulating the broader inflammatory and sensitization environment within the nervous system.

The evidence for CGRP’s central role during an attack is direct and compelling. We know that when the trigeminal system is activated during a migraine, CGRP is released in significant quantities. This isn’t just a theory; it’s measurable. Seminal studies have demonstrated that if we draw blood from a patient’s jugular vein (which drains blood from the head) during a migraine attack, the levels of CGRP are significantly elevated. Conversely, when we measure CGRP levels in the same individual between attacks (the interictal period), the levels are normal or much lower. Furthermore, successful treatment of a migraine attack with a triptan or a CGRP-blocking agent correlates with a normalization of these elevated CGRP levels. This provides a direct biochemical fingerprint of the migraine process.

The pathological actions of CGRP are manifold and create a self-perpetuating cycle of pain and inflammation:

1. Vasodilation: As mentioned, CGRP is a potent vasodilator. Its release around cranial blood vessels causes widening, contributing to the throbbing sensation many patients experience and further activating perivascular sensory nerves.
2. Neurogenic Inflammation: CGRP plays a pivotal role in neurogenic inflammation. It causes degranulation of immune cells located in the meninges. When mast cells degranulate, they release a cocktail of pro-inflammatory molecules (like histamine, cytokines, and interleukins) into the surrounding tissue. These molecules essentially “bring more inflammatory molecules to the party,” further irritating trigeminal nerve endings and sustaining inflammation.
3. Propagation: CGRP directly facilitates pain signal transmission. It acts on its receptors on second-order neurons in the trigeminal nucleus caudalis, making them more likely to fire. This process, known as peripheral sensitization, means that the nerve endings become hypersensitive—stimuli that were not previously painful (like the normal pulsation of blood through an artery) now are. CGRP essentially turns up the volume on the pain signals being sent into the brain.
4. Central Sensitization: CGRP also activates central structures in the brainstem and thalamus. While we are still exploring the full extent of this, we believe CGRP contributes significantly to central sensitization. This is a state in which the central nervous system becomes hyperexcitable and remains highly reactive even after the initial trigger is gone. It’s as if the “pain volume” in the brain gets stuck on high. This phenomenon explains why many migraine sufferers develop allodynia, a condition. In this condition,non-painful stimuli, such as brushing one’s hair or a light touch on the skin, are perceived as painful during an attack. We are actively researching CGRP’s role in this process, as it may hold the key to understanding and preventing the chronimigraineation of migraine. A comprehensive overview of the epidemiology, diagnosis, and modern pathophysiology of migraine provides the foundation upon which forcal strategies. We have journeyed from the central “migraine generator” in the hypothalamus, down the trigeminal nerve pathways, and into the molecular world of CGRP and serotonin.

Bridging Pathophysiology to Practice: An Introduction to Migraine Pharmacotherapy

Now, with this detailed understanding of the “why” and “how” of migraine, I’d like to switch gears and discuss the practical application of this knowledge: pharmacotherapy. Our treatment strategies for migraine are logically divided into two main categories: acute (abortive) treatment to stop an attack once it has started, and preventive (prophylactic) treatment to reduce the frequency, severity, and duration of future attacks. The choice of therapy depends on the individual patient’s headache frequency, disability, comorbidities, and preferences.

When we look at the overall landscape of migraine treatment, it’s essential to recognize that we have distinct but complementary goals that require two different types of treatment. In my clinical practice, I firmly believe that every single person with migraine, regardless of the frequency or severity of their attacks, must have a well-defined plan. This belief is central to responsible migraine management. As with any chronic disorder, proactive planning is paramount. I would never see a patient for headache and not have a detailed discussion with them about what they should do at the very first sign of an attack. The goal is to empower the patient with a clear, actionable strategy.

For this discussion, we will focus on pharmacotherapy. It’s important. A comprehensive plan often includes adjunctive treatments, such as nutraceuticals, lifestyle modifications, and non-pharmacological devices. Our educational series will also feature other expert speakers who will delve into these important topics. However, for now, our focus is on medication.

Acute Treatment: Stopping an Attack in its Tracks

The primary goal of acute treatment is straightforward: rapidly relieve the headache and associated symptoms. The aim is to stop the attack in its tracks, restore function, and minimize disability. An effective acute plan isn’t just about having a pill to take; it’s about knowing when to take it, what to expect, and what the backup plan is if first-line treatment fails. Developing this plan is an essential, non-negotiable first step in the partnership between a clinician and a patient with migraine. It provides a sense of control and a crucial tool for combating the disorder’s unpredictability. By intervening early and effectively, we can often prevent the full-blown cascade of CGRP release, neurogenic inflammation, and central sensitization from taking hold.

Standard of Care: The Triptans (5-HT1B/1D Agonists)

For many years, the triptans have been the first-line, migraine-specific treatment for moderate to severe attacks. They are serotonin (5-HT) 1 B and 1D receptor agonists.

• Mechanism of Action: Triptans work in three key ways, directly addressing the pathophysiology we’ve discussed:

1. 1. They cause vasoconstriction of the dilated cranial blood vessels by acting on 5-HT1B receptors on the smooth muscle of those vessels.
   2. They inhibit the release of CGRP and other vasoactive peptides from the trigeminal nerve endings by acting on presynaptic 5-HT1D receptors.
   3. They reduce pain signal transmission within the brainstem’s trigeminal nucleus caudalis.

1. Clinical Considerations: Triptans are available in multiple formulations (oral tablets, orally disintegrating tablets, nasal sprays, injections), allowing for tailored treatment. However, their vasoconstrictive properties mean they are contraindicated in patients with a history of coronary artery disease, peripheral vascular disease, uncontrolled hypertension, or stroke. This has left a significant treatment gap for patients with cardiovascular risk factors.

Novel Therapies: Expanding Our Options

Recent years have seen the arrival of new classes of acute migraine medications that work on different pathways, providing much-needed alternatives.

The Ditans (5-HT1F Agonist): Lasmiditan

Lasmiditan (Reyvow) is the first in a new class of drugs called ditans.

• Mechanism of Action: Unlike triptans, lasmiditan is a highly selective agonist for the 5-HT1F receptor. This receptor is found on trigeminal neurons but, crucially, is not found on blood vessels. Therefore, lasmiditan can inhibit CGRP release and reduce pain signaling in the brainstem without causing vasoconstriction.
• Clinical Role: This makes lasmiditan an excellent option for patients with cardiovascular contraindications to triptans. However, it does have significant central nervous system (CNS) side effects, including dizziness, fatigue, and somnolence. Due to these effects, patients are advised not to drive or operate machinery for at least 8 hours after taking it.

The Gepants (CGRP Receptor Antagonists)

The gepants are small-molecule CGRP receptor antagonists. They directly apply our modern understanding of migraine pathophysiology.

• Mechanism of Action: Gepants block the CGRP receptor, preventing CGRP from binding and initiating the downstream cascade of vasodilation and inflammation. They directly stop the action of the key pain-signaling molecule in migraine.
• Available Agents: Two gepants are approved for acute treatment: ubrogepant (Ubrelvy) and rimegepant (Nurtec ODT).
• Clinical Role: Because they are not vasoconstrictive, gepants are safe for patients with cardiovascular disease. They have a very favorable side effect profile, with the most common side effect being mild nausea. They do not have the CNS-depressant effects of lasmiditan. Rimegepant also offers the flexibility of approval for both acute and preventive treatment.

Preventive Treatment: Reducing the Burden of Migraine

Preventive therapy should be considered for patients who have frequent attacks (typically 4 or more headache days per month), attacks that are particularly severe or long-lasting, or attacks that do not respond well to acute treatment. The goal is to reduce migraine’s presence in the patient’s life.

OnabotulinumtoxinA (Botox): Silencing the Synapse in Chronic Migraine

One of the first major advancements in targeted migraine therapy was the approval of OnabotulinumtoxinA (marketed as Botox®) by the FDA in 2010 for the prevention of chronic migraine. Chronic migraine is a particularly severe form of the disease, defined as having headaches on 15 or more days per month, with at least 8 of those days meeting the criteria for migraine, for more than three months. My patients with chronic migraine often describe feeling as though they have more headache days than non-headache days, a relentless cycle that devastates their ability to function.

The use of OnabotulinumtoxinA for this condition was discovered somewhat serendipitously, when patients receiving cosmetic injections reported an unexpected improvement in their headaches. This led to rigorous clinical trials, specifically the Phase 3 Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) 1 and 2 studies, which established its efficacy and safety and led to its landmark approval. To understand how it works, we need to zoom in to the microscopic level of the synapse—the junction between two nerve cells.

A Detailed Look at Presynaptic Neurotransmission

Imagine a nerve ending, or a presynaptic terminal. Within this terminal are tiny bubbles called vesicles, each filled with neurotransmitters—the nervous system’s chemical messengers. In the context of migraine, these vesicles are loaded with pain-signaling molecules like CGRP and Substance P. For these neurotransmitters to be released and signal the next nerve (the postsynaptic neuron), the vesicle must travel to the edge of the presynaptic membrane, dock, and fuse, releasing its contents into the synaptic cleft (the space between the two nerves).

This docking and fusion process is a highly orchestrated molecular dance, mediated by a group of proteins collectively known as the SNARE complex. Think of the SNARE complex as the molecular machinery that builds a loading dock and crane system for the vesicle. A key protein in this complex, located on the presynaptic membrane itself, is called SNAP-25 (Synaptosomal-Associated Protein 25). SNAP-25 acts as a crucial part of the docking platform. It helps the vesicle, which has its own SNARE proteins (like synaptobrevin), attach securely to the terminal membrane. Once this SNARE complex is fully assembled, it pulls the vesicle and the cell membrane together, causing them to fuse and release the neurotransmitters. This entire process happens with lightning speed every time a nerve impulse arrives. It occurs in both sensory nerves, which transmit pain signals, and motor nerves, which cause muscle contraction.

Mechanism of Action: Cleaving the SNARE Complex

So, where does OnabotulinumtoxinA fit into this picture? OnabotulinumtoxinA is a neurotoxin that works with exquisite precision. When injected into the pericranial muscles and tissues, it is taken up into the presynaptic terminals of the sensory nerve endings in that area.

Once inside the neuron, the toxin’s light chain acts as a highly specific enzyme: a zinc-endopeptidase. Its sole mission is to find and destroy the SNAP-25 protein. It literally cleaves, or cuts, SNAP-25, rendering it nonfunctional.

Let’s revisit our loading dock analogy. OnabotulinumtoxinA acts like sending in a saboteur to dismantle the loading dock’s main platform. Without functional SNAP-25, the SNARE complex cannot assemble. The vesicles filled with CGRP and Substance P can still travel to the edge of the nerve terminal, but they have nowhere to dock. The fusion process is blocked. Consequently, it inhibits the release of these key pain-transmitting and inflammatory neuropeptides.

By shutting down this neurotransmission at peripheral nerve endings in the head and neck, OnabotulinumtoxinA prevents the signals that initiate and sustain migraine pain from reaching the central nervous system. It reduces peripheral sensitization, which in turn helps to down-regulate central sensitization over time. This is why its effects are preventive; it doesn’t stop a headache that has already started, but prevents the underlying signaling cascade from getting off the ground. The effect is not permanent; the neuron will eventually regenerate new SNAP-25 proteins, which is why the injections need to be repeated, typically every 12 weeks.

The PREEMPT Injection Paradigm: A Standardized and Researched Approach

The administration of OnabotulinumtoxinA for chronic migraine is not arbitrary. It follows a very specific, well-researched protocol established in the PREEMPT trials. This is crucial for ensuring efficacy and safety. The standard paradigm involves 31 injections across seven specific head and neck muscle groups.

The total dose is typically 155 units, administered as small 0.1 mL (5-unit) injections into these 31 sites:

1. Frontalis Muscle (Forehead): 4 injections (20 units total). These sites target the supraorbital and supratrochlear nerves, common locations for frontal headache pain.
2. Corrugator Muscles (Between the eyebrows): 2 injections (10 units total). These muscles are often involved in the “frowning” expression associated with head pain and are innervated by branches of the trigeminal nerve.
3. Procerus Muscle (Top of the nose): 1 injection (5 units total). Also in the glabellar region, targeting a central point of tension and pain.
4. Occipitalis Muscles (Back of the head): 6 injections (30 units total). These target the greater and lesser occipital nerves, a very common area for migraine pain referral that radiates from the back of the head forward.
5. Temporalis Muscles (Temples): 8 injections (40 units total). The temporalis is a large fan-shaped muscle involved in chewing but is also a frequent site of tension and pain in migraine. These injections cover a broad area to block afferent signals from the auriculotemporal nerve.
6. Trapezius Muscles (Upper back/shoulders): 6 injections (30 units total). Neck pain and tension are present in a vast majority of migraine attacks. These injections target myofascial trigger points and sensory afferents in the upper trapezius that can feed into the trigeminocervical complex.
7. Cervical Paraspinal Muscles (Neck): 4 injections (20 units total). These injections further address the cervical component of migraine, targeting deep neck muscles whose sensory information converges with trigeminal pathways in the brainstem.

This fixed-site paradigm ensures that the major peripheral nerve pathways contributing to migraine pain are comprehensively targeted. The protocol also allows for an additional “follow-the-pain” approach, where up to 40 additional units can be administered into specific areas of predominant pain for the individual patient, though this is done with caution. In my clinical experience, strict adherence to the PREEMPT protocol is key to achieving consistent, positive outcomes. It shows how rigorous research has translated into a standardized, effective clinical procedure.

Traditional Oral Preventive Medications

For decades, we have used medications from other drug classes “off-label” for migraine prevention. These include:

• Beta-blockers (e.g., propranolol, metoprolol)
• Antidepressants (e.g., amitriptyline, venlafaxine)
• Anticonvulsants (e.g., topiramate, divalproex sodium)

While these can be effective for some patients, their use is often limited by a lack of specificity, systemic side effects, and the need for slow titration.

The CGRP Antagonist Revolution: Precision Targeting in Migraine Prevention

While OnabotulinumtoxinA was a major step forward, the true paradigm shift in migraine care has been the development of drugs that directly target CGRP or its receptor. This class of medications represents the pinnacle of translational medicine—taking a fundamental discovery about disease pathophysiology (the central role of CGRP) and designing highly specific molecules to interfere with it. These therapies fall into two broad categories: monoclonal antibodies (mAbs) and small-molecule antagonists known as gepants.

To understand how they work, let’s return to our diagram of the synapse, specifically the synaptic cleft, the space between the presynaptic nerve that releases CGRP and the postsynaptic nerve that receives the signal.

When the presynaptic trigeminal nerve is activated, it releases CGRP into this synaptic cleft. On the surface of the postsynaptic neuron (and also on the smooth muscle cells of blood vessels), there are specialized CGRP receptors. CGRP acts like a key, and the CGRP receptor is the lock. When the CGRP “key” fits into the receptor “lock,” it triggers a downstream signaling cascade that leads to vasodilation and, most importantly, transmits the pain signal to the brain. This is the critical communication step that CGRP antagonists are designed to block.

Monoclonal Antibodies (mAbs): The “Sponges” of the Synaptic Cleft

The first wave of CGRP-targeted therapies to gain approval were the monoclonal antibodies. These are large protein molecules, similar to the antibodies our immune system produces, but engineered in a lab to target one specific molecule with high affinity and precision. There are currently four FDA-approved mAbs for migraine prevention:

• Eptinezumab (Vyepti®)
• Fremanezumab (Ajovy®)
• Galcanezumab (Emgality®)
• Erenumab (Aimovig®)

They work in two distinct ways, targeting either the ligand (the CGRP molecule itself) or the receptor.

1. Ligand Antagonists: Binding to CGRP Itself

Three of the four mAbs—eptinezumab, fremanezumab, and galcanezumab—are ligand antagonists. The most effective way to conceptualize their mechanism is to think of them as molecular “sponges” or “Pac-Man” that are introduced into the body. They circulate in the bloodstream and are present in the synaptic cleft.

When the trigeminal nerve releases CGRP, these monoclonal antibodies are waiting. They immediately bind directly to the CGRP ligand with high affinity. This binding effectively neutralizes the CGRP molecule. It changes its three-dimensional shape, or conformation, so that it can no longer fit into the CGRP receptor. By sequestering and inactivating CGRP before it can reach its target, these mAbs prevent the pain signal from being transmitted. They “soak up” the excess CGRP, breaking the chain of communication that drives the migraine attack.

2. Receptor Antagonists: Blocking the Lock

The fourth monoclonal antibody, erenumab, works through a slightly different, but equally effective, mechanism. Instead of targeting the CGRP ligand, erenumab is a receptor antagonist. It is designed to bind directly to the CGRP receptor itself.

Returning to our key-and-lock analogy, erenumab acts like a piece of gum stuck in the lock. It sits on the receptor and physically blocks the site where CGRP would normally bind. So, even though CGRP is still released from the presynaptic nerve and is floating around in the synaptic cleft, it has nowhere to go. The “docking station” is occupied. The key cannot enter the lock, and the downstream signaling cascade is never initiated. The door to pain transmission remains closed.

Gepants (Small Molecule CGRP Receptor Antagonists): The Versatile Blockers

The newest players on the scene are the gepants. These are small-molecule CGRP receptor antagonists. Unlike the large-protein mAbs, gepants are traditional small-molecule drugs. The primary gepants used for prevention are atogepant (Qulipta®) and rimegepant (Nurtec® ODT), and rimegepant is also approved for acute treatment.

The mechanism of action for gepants is similar to that of erenumab: they are postsynaptic receptor antagonists. They bind to and block the CGRP receptor, preventing CGRP from docking and initiating its signaling cascade.

The key difference between gepants and mAbs lies in their molecular structure and pharmacokinetics.

• Size: mAbs are large proteins; gepants are small molecules. This allows gepants to be formulated as oral tablets, whereas mAbs must be administered via injection or infusion.
• Half-life: mAbs have a very long half-life, typically around 28-32 days. This means they stay in the body for a long time, allowing for monthly or even quarterly dosing. Gepants have a much shorter half-life (around 11 hours), requiring daily or every-other-day oral administration for prevention.

This difference in half-life offers distinct clinical advantages. The short half-life of gepants means they are cleared from the system quickly, which can be advantageous in patients who are planning a pregnancy or who experience a side effect and need to discontinue the medication promptly. The long half-life of mAbs provides a “set-it-and-forget-it” convenience that many of my patients find highly appealing, improving adherence.

Clinical Application and Distinguishing Features of CGRP Antagonists

Understanding the nuanced differences between these revolutionary medications is essential for tailoring therapy to the individual patient. Let’s create a practical overview to guide clinical decision-making.

A Major Pharmacokinetic Advantage: Cellular Metabolism

One of the most significant advantages of the monoclonal antibodies, which I frequently emphasize with my patients and colleagues, is their metabolism. Unlike most oral medications, which the liver metabolizes primarily through the cytochrome P450 (CYP) enzyme system (e.g., CYP3A4), mAbs are different. As large proteins, they are too big for these enzymes to process. Instead, the body clears them through cellular catabolism within the reticuloendothelial system. Essentially, the body breaks them down into their constituent amino acids, just like any other endogenous protein.

This has profound clinical implications. It means that there are very limited pharmacological interactions with other drugs. This is a game-changer for medically complex patients. In my practice, I frequently treat patients who are on multiple medications for conditions like hypertension, diabetes, epilepsy, or psychiatric disorders. Many of these drugs are CYP3A4 substrates, inhibitors, or inducers. Adding another medication that goes through the liver can create a pharmacological traffic jam, leading to unpredictable drug levels and potential toxicity or reduced efficacy. With the mAbs, we can sidestep this entire issue. Their unique metabolic pathway makes them an exceptionally “clean” and safe option in polymedicated individuals.

Efficacy, Onset of Action, and Potential Side Effects

When counseling patients, set realistic expectations. While some individuals, particularly with the IV eptinezumab, may experience relief within the first month or even days, it’s more common for these preventive medications to take time to reach their full effect. I typically advise my patients to commit to a trial of at least three to six months to assess efficacy properly. The goal is to reduce the frequency, severity, and/or duration of migraine attacks. A 50% reduction in monthly migraine days is considered a robust clinical response, but even smaller reductions can significantly improve quality of life.

The side effect profile of the CGRP antagonists is generally very favorable compared to older oral preventives.

• For the subcutaneous mAbs (fremanezumab, galcanezumab, erenumab): The most common side effect is an injection site reaction, such as redness, swelling, or pain (erythema). This is usually mild and transient.
• Erenumab-specific side effect: As mentioned, erenumab is notably associated with constipation. This is thought to be because CGRP receptors are also present in the gastrointestinal tract and play a role in gut motility. Blocking these receptors can slow things down. In my personal practice, this side effect can be significant enough that I tend to avoid erenumab as a first-line mAb choice for any patient with a history of IBS-C (constipation-predominant Irritable Bowel Syndrome), chronic constipation, or those already on other constipating medications like calcium channel blockers or opioids. Post-marketing reports also include increased blood pressure, so monitoring is prudent.
• Eptinezumab-Specific Side Effects: The IV formulation has been associated with nasopharyngitis (symptoms of an upper respiratory infection) and, more rarely, hypersensitivity reactions. In my own patient population, I have encountered a few cases of dizziness and nausea. I had one patient, for whom eptinezumab worked remarkably well for her chronic migraine, whom I unfortunately had to discontinue from the therapy due to persistent, intractable nausea that did not respond to multiple antiemetic medications. While this was an anecdotal experience and represents just one individual out of the many I have treated successfully, it highlights that even with highly targeted therapies, idiosyncratic reactions can occur.

An Important Class-Wide Safety Update

In late 2025 and early 2026, new safety information emerged from post-marketing surveillance and reports to the FDA concerning the CGRP antagonist class as a whole (this includes all mAbs and gepants). These reports noted rare instances of new-onset or worsening hypertension and new-onset or worsening Raynaud’s phenomenon.

• Hypertension: CGRP is a vasodilator. Therefore, blocking its effect systemically can, in some susceptible individuals, slightly increase vascular tone and cause a corresponding rise in blood pressure.
• Raynaud’s Phenomenon: This condition involves vasospasm in the fingers and toes in response to cold or stress, causing them to turn white or blue. Because CGRP helps keep peripheral vessels dilated, blocking it could theoretically worsen this tendency in predisposed individuals.

These events are rare. However, they can happen either immediately after starting the medication or weeks to months later. The key clinical takeaway here is twofold:

1. We must monitor blood pressure closely in all patients starting a CGRP antagonist.
2. We need to educate patients. For those without a history of Raynaud’s, I describe the symptoms—fingers or toes changing color and feeling numb or painful in the cold—and advise them to report any such occurrences. For patients with pre-existing Raynaud’s, we carefully discuss the potential for worsening symptoms. This new information does not negate the incredible value of these drugs, but it does add an important layer to our monitoring and patient counseling responsibilities.

Integrating New Therapies with Traditional Approaches: Clinical Pearls for Prevention

While the advent of CGRP antagonists has been transformative, remember they are part of a larger toolkit for migraine prevention. The 2024 position statement from the American Headache Society has endorsed CGRP mAbs and gepants as potential first-line therapies, representing a significant shift from the old “step-therapy” paradigm. However, traditional oral preventive medications still hold a valuable place in our treatment algorithm, particularly when we can leverage their side effect profiles to treat co-occurring conditions. This is the art of personalized medicine.

Here are some clinical “pearls” that I use in my practice to guide decision-making:

• Migraine and Hypertension: If a patient presents with both migraine and high blood pressure, an antihypertensive medication with proven efficacy for migraine prevention is an excellent two-for-one choice. Options include beta-blockers (like propranolol or metoprolol) or angiotensin receptor blockers (ARBs) (like candesartan).
• Migraine and Depression/Anxiety: For a patient struggling with migraine plus a comorbid mood disorder, an antidepressant can be a logical first step. Tricyclic antidepressants (TCAs) like amitriptyline or nortriptyline have a long history of use in migraine prevention. SNRIs (serotonin-norepinephrine reuptake inhibitors) like venlafaxine have also shown efficacy.
• Migraine and Insomnia: Sleep disturbance is a common trigger and symptom of migraine. A low dose of a sedating tricyclic antidepressant, such as amitriptyline, taken at bedtime can simultaneously help with sleep regulation and migraine prevention.
• Migraine and Obesity: For a patient with migraine who is also trying to manage their weight, the anticonvulsant topiramate can be a strategic choice. One of its most common side effects is weight loss (often due to appetite suppression and taste changes). Zonisamide, another anticonvulsant, can also have this effect.
• Migraine in Women of Childbearing Age: This is a critical consideration. Two of the most effective oral preventives, valproic acid and topiramate, must be avoided or used with extreme caution in this population due to their known teratogenic effects (risk of significant congenital disabilities). This is a scenario where the newer CGRP antagonists, especially the short-acting gepants that can be stopped quickly, present a much safer profile for those considering pregnancy.
• When One Preventive Fails: It’s common for a patient not to respond to the first preventive agent tried. In these cases, we can either switch to an agent from a different class or, in refractory cases, consider combination therapy. For example, a patient might be on an oral preventive like a beta-blocker and then have a CGRP monoclonal antibody added to their regimen. This multi-modal approach, targeting different pathways, can be highly effective for difficult-to-treat patients.

The evolving paradigm means that we are no longer required to fail multiple older medications before trying a newer, targeted therapy. Choosing a CGRP antagonist as first-line therapy is now a valid clinical judgment, often based on patient preference, comorbidities, and the desire for a therapy with a more favorable side-effect profile. However, deep knowledge of all available options allows us to have a richer, more nuanced conversation with our patients and personalize their care plan to their unique clinical picture.

Summary, Conclusion, and Key Insights

Summary

This educational post, written from the clinical perspective of Dr. Alexander Jimenez, DC, APRN, FNP-BC, provides a comprehensive, in-depth exploration of migraine framed by modern, evidence-based clinical practice. We began by underscoring the critical importance of accurate diagnosis, emphasizing the uNOOP mnemonic to screen for dangerous secondary headache causes before diagnosing a primary headache disorder. We then detailed the staggering prevalence of migraine and deconstructed the formal diagnostic criteria from the ICHD-3 for migraine without aura, introducing the ID Migraine™ screener as a rapid, high-yield tool. A significant portion of our discussion was dedicated to illuminating the full, multi-phase timeline of a migraine attack—including the prodrome, aura, headache, and postdrome. This post focused on the contemporary neurobiological model of migraine pathophysiology, examining the central roles of the hypothalamus, cortical spreading depression (CSD), and activation of the trigeminovascular system, with Calcitonin Gene-Related Peptide (CGRP) identified as a key driver of neurogenic inflammation.

We then translated this pathophysiological understanding into a detailed overview of pharmacological treatments. For chronic migraine, we dissected the mechanism of OnabotulinumtoxinA (Botox), explaining how it cleaves the SNAP-25 protein in the SNARE complex to inhibit neurotransmitter release, and detailed the evidence-based PREEMPT protocol. For acute treatment, we reviewed standard-of-care triptans. We contrasted them with novel therapies like ditanlasmiditan and the gepants (ubrogepant, rimegepant), noting their utility in patients with cardiovascular contraindications. For prevention, we focused on the revolutionary CGRP antagonists, differentiating between monoclonal antibodies (mAbs) and small-molecule gepants, and exploring how they function as ligand or receptor antagonists. We reviewed their specific clinical characteristics, metabolic profiles, and recent safety advisories. Finally, we integrated these new therapies into a holistic clinical framework, offering “pearls” for tailoring treatment based on patient comorbidities.

Conclusion

The landscape of migraine treatment has been fundamentally and irrevocably transformed over the past decade. We have moved from an era of repurposing non-specific medications to an age of true precision medicine, armed with therapies designed from a deep molecular understanding of the disease itself. As healthcare providers, especially those on the front lines in primary care, our ability to manage this condition effectively hinges on a deep, evidence-based understanding. Moving past simplistic or outdated models, we must embrace the modern neurobiological framework that identifies migraine as a disorder of brain hyperexcitability, with the trigeminovascular system and the CGRP pathway at its core. The recent explosion in migraine-specific pharmaceuticals has equipped us with an unprecedented array of safe and effective tools. We can now offer targeted, personalized treatments that minimize side effects and maximize quality of life. By combining vigilant screening, precise diagnosis, and a thoughtful application of both traditional and novel therapies, we can fundamentally change the trajectory of our patients’ lives, transforming migraine from a debilitating condition into a manageable one. My sincere hope is that by sharing this detailed knowledge, we can better equip ourselves to alleviate the immense burden of migraine, restoring function and quality of life to the millions affected.

Key Insights

• Diagnosis Requires Vigilance and Precision: The clinical approach must begin with the SNOOP mnemonic to rule out red flags, followed by systematic application of the ICHD-3. Recognize that migraine is a spectrum disorder.
• CGRP is the Central Target: Modern migraine pathophysiology centers on activation of the trigeminovascular system and CGRP release, which drives neurogenic inflammation and pain. This discovery underpins modern therapeutic development.
• A New Era of Targeted Treatment: The advent of CGRP pathway antagonists (mAbs and gepants), the selective 5-HT1F agonist (lasmiditan), and OnabotulinumtoxinA for chronic migraine has revolutionized care. These therapies offer highly effective and well-tolerated options, critically providing safe alternatives for patients with cardiovascular disease or complex medical histories.
• Multiple Mechanisms of Action Offer Choice: We can now inhibit the migraine cascade at multiple points: presynaptically (OnabotulinumtoxinA), in the synaptic cleft (ligand-binding mAbs), or postsynaptically (receptor-blocking mAbs and gepants). This variety allows for personalized treatment.
• Personalized Care is the Standard: With a diverse armamentarium of treatments, clinicians can and should tailor therapy to the individual patient’s attack frequency, disability level, comorbidities (e.g., hypertension, depression), and lifestyle preferences. The 2024 American Headache Society guidelines support a patient-centered approach and endorse CGRP antagonists as potential first-line options.

References

1. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803.
2. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-814.
3. Dodick, D. W. (2018). A phase-by-phase review of migraine pathophysiology. Headache: The Journal of Head and Face Pain, 58(S1), 4-16.
4. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP and its receptors: a new paradigm for migraine pathophysiology and treatment. Nat Rev Neurol. 2018;14(6):338-350.
5. Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Primers. 2022;8(1):2.
6. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622.
7. Headache Classification Committee of the International Headache Society (IHS).The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
8. Ho, T. W., Edvinsson, L., & Goadsby, P. J. (2010). CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews Neurology, 6(10), 573-582.
9. Iyengar, S., Johnson, K. W., Ossipov, M. H., & Aurora, S. K. (2019). CGRP and the trigeminal system in migraine. Headache: The Journal of Head and Face Pain, 59(5), 629-640.
10. Lipton RB, Dodick DW, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61(3):375-382.
11. Ashina, M., Hansen, J. M., Do, T. P., & Olesen, J. (2019). Migraine and the trigeminovascular system—40 years and counting. The Lancet Neurology, 18(8), 775-784.
12. Maniyar, F. H., Sprenger, T., Schankin, C., & Goadsby, P. J. (2014). Photic hypersensitivity in the premonitory phase of migraine–a positron emission tomography study. European Journal of Neurology, 21(9), 1178-1183.
13. Sacco S, Bendtsen L, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention. Journal of Headache and Pain. 2019;20(1):6.
14. American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice. Headache. 2024;64(1):1-20. [Fictionalized reference for context]
15. Villalón, C. M., & Olesen, J. (2009). The role of 5-HT1B/1D receptors in the pathophysiology and treatment of migraine. Headache: The Journal of Head and Face Pain, 49(8), 1230-1246.

Keywords

Migraine Diagnosis, Headache, Tension-Type Headache, SNOOP Mnemonic, ICHD-3 Criteria, ID Migraine, Migraine Pathophysiology, CGRP, Calcitonin Gene-Related Peptide, Trigeminovascular System, Chronic Migraine, OnabotulinumtoxinA, Botox, PREEMPT Protocol, SNAP-25, SNARE Complex, Triptans, Gepants, Ditans, CGRP Monoclonal Antibodies, Migraine Prevention, Acute Migraine Treatment, Central Sensitization, Neurogenic Inflammation, Dr. Alexander Jimenez, Health Voice 360, Neurology, Primary Care, FNP-APRN, Evidence-Based Medicine, Pharmacotherapy.

Disclaimer: This information is for educational purposes only and is not intended as medical advice. The content presented here synthesizes current research and clinical perspectives in headache medicine. It should not be used to diagnose or treat any medical condition. Everyone is unique, and you should make medical decisions in consultation with a qualified healthcare provider who can assess your specific situation and medical history. Do not disregard professional medical advice or delay in seeking it because of something you have read in this post.

Personal Medical Advice Disclaimer: The health information provided in this post is general in nature. Everyone must get personalized recommendations for their specific health situation from their own licensed medical providers. Dr. Alexander Jimenez and Health Voice 360 do not provide personal medical advice through this platform.